In 1993, a 54-year-old patient presented with stage IIIA myeloma (MM). After melphalan/prednisolone therapy, he achieved a plateau phase, but progressed in 1996 and PBSC were harvested after mobilization (cyclophosphamide/G-CSF). After conditioning with TMI (total marrow irradiation, 9 Gy), busulfan, and cyclophosphamide, 1 autologous PBSC were transfused and complete remission was documented. Maintenance therapy (IFN-a) had to be discontinued due to intolerable side effects. The patient progressed again 11/1998, received four cycles of chemotherapy (vinorelbine, idarubicine, dexamethasone) and received high-dose melphalan followed by a second autologous PBSCT (partial remission).
Progression in 03/2000 did not respond to thalidomide, topotecan, high-dose dexamethasone/gemcitabine, and bendamustin had to be discontinued (allergic reaction). In 01/2001, the patient required weekly platelet and red blood cell transfusions. With no further conventional therapeutic options and no suitable HLA-matched donor, experimental therapy with 186 Re-HEDP (rhenium-186 hydroxyethylidene diphosphonate) was initiated, followed by high-dose melphalan and a third autologous PBSCT. Re production, a test dose (3.6 GBq) for dosimetry was administered 5 h before treatment infusion (26 GBq). Figure 1 demonstrates the whole-body scintigram 48 h after injection. Regions of interest (ROI) were placed over the spine, sacrum, and lateral abdomen (bone, soft tissue). Bone uptake was modeled from the time courses of these ROI data. The infinite biological half-life in bone was used to calculate the bone marrow dose (planned target dose: 20 Gy). To determine the earliest moment for PBSCT, the residual dose to the bone marrow (maximum 1 Gy) was calculated from the time course of radioactivity retained in the patient and the fraction of the treatment dose bound to the bone (determined by urine sampling for 48 h).
At 10 days after 186
Re-HEDP administration, high-dose melphalan was given (100 mg/m 2 ). After 2 days, autologous PBSC were transfused (02/2001). No severe extrahematological toxicity was observed. WBC recovery was documented on day þ 11. After discharge, the patient required no transfusions, and complete remission was documented (04/2001: negative immunofixation).
Unfortunately, meningeal involvement developed. The patient received i.t. cytosinarabinoside, dexamethasone, and methotrexate, radiation of the brain (30 Gy) and four courses of temozolamide, but died of further disease progression in 07/2002. Several innovative strategies have modified the management of MM. In younger patients with advanced MM, double high-dose therapies are now part of the front-line therapy. 2 Some patients achieve molecular remission after allogeneic SCT. 3 With no suitable donor, this patient received myeloablation with bone-seeking radiopharmaceuticals followed by autologous PBSCT when progression occurred after the second high-dose therapy.
Myeloablation by bone-seeking radiopharmaceuticals was first demonstrated in animals. 4, 5 Studies in MM patients confirmed feasibility. 6, 7 While 186 Re-HEDP-like 153 Sm-EDTMP is widely used for bone palliation, the use of potentially myeloablative doses has been published only once. 8 Treatment with 186 Re-HEDP aiming at myeloablation has not been reported, although 186 Re leads to more homogeneous irradiation of the bone marrow. Considering renal and bladder toxicity, 9 the longer half-life is an advantage, although the resulting longer interval until SCT can be performed might be a drawback. No severe nonhematological side effects were observed and contin- Figure 1 uous bladder irrigation was successful in preventing hemorrhagic cystitis. 9 The residual radiation dose to the bone marrow space after radionuclide treatment acceptable for SCT is not known. The limit of 1 Gy was a careful estimate based on literature data. 7 This dose is higher than the ones usually used for radioimmunotherapy, which might be explained by the nonhomogeneous dose distribution delivered to the bone marrow space by bone-bound beta-emitters, giving transfused stem cells the chance of survival in the low-dose areas.
Complete remission was achieved in this patient with MM progressing after two cycles of high-dose therapy and refractory to all available therapeutic options at that time. Treatment response could at least partly be attributed to the radiation. Complete remission rates have also been observed by others in MM after 166 Ho-DOTMP, high-dose melphalan, and PBSCT. 9 Unfortunately, this patient progressed again with meningeal disease, suggesting that the CNS is a sanctuary site for tumor cells even after high-dose chemo-and radiotherapy.
In conclusion, myeloablation with bone-seeking radiopharmaceutical agents seems to offer a beneficial therapeutic option in patients with MM, progressing even after tandem autologous PBSCT.
